Disorder of lacrimal gland

This phase 1 trial is testing an experimental drug called ATG-201 in adults with systemic lupus erythematosus, systemic sclerosis, or Sjögren's disease. ATG-201 is designed to bind to specific proteins on immune cells, potentially quieting the overactive immune response that driv…

Researchers are testing an experimental antibody called JH013 in adults with primary Sjögren's syndrome, a condition where the immune system attacks moisture-producing glands and other tissues. The trial has two parts: one gives a single injection at increasing doses, and the oth…

This trial gives deucravacitinib, an oral drug that calms the immune system, to adults with lupus or Sjögren's disease and to children with psoriasis or psoriatic arthritis. Participants join after finishing an earlier study of the same drug, and the goal is to see how safe and t…

This early-stage study tests whether a single infusion of a patient's own modified immune cells (CAR-T cells) is safe for people with severe autoimmune diseases like lupus, rheumatoid arthritis, or scleroderma that haven't improved with standard treatments. Only 6 adults aged 18-…

This trial tests whether an experimental drug called efgartigimod can reduce nerve damage and pain in adults with Sjogren's disease. Participants will receive either the drug or a placebo as a subcutaneous injection. The study measures changes in neuropathy symptoms and quality o…

This early-stage trial is evaluating an investigational drug called QLS2404, given as an injection, to see if it is safe and tolerable. The study first tests single doses in healthy volunteers, then moves to multiple doses in people with systemic lupus erythematosus or primary Sj…

This phase 2 trial is testing whether an oral drug called ICP-488 can reduce disease activity in people with primary Sjögren's syndrome, an autoimmune condition that causes dry eyes, dry mouth, and fatigue. About 240 adults aged 18 to 70 with moderate-to-active disease will recei…

This early-phase trial tests a single dose of universal (off-the-shelf) CAR-T cells in 30 adults with active autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's. The treatment targets CD19 and BCMA on immune cells to reset the faulty immune system. The…

This phase 2 trial tests whether eye drops containing infliximab, a drug that blocks a key inflammatory protein, can safely improve severe dry eye in people with Sjögren's syndrome. 38 adults will receive either the active drops or a steroid drop for 6 weeks. The study measures s…

This first-in-human study tests the safety of a new drug called HBM7020. It will first be given to healthy volunteers at low doses, then to people with moderate to severe autoimmune diseases like lupus, rheumatoid arthritis, scleroderma, and Sjögren's disease. The goal is to see …

This early-stage study tests a new injection called CM336 in 30 adults with active Sjogren's syndrome. The main goal is to check safety and how the body handles the drug. Researchers will also look for signs that it helps control the disease. This is a Phase 1 trial, so it's one …

This early-phase trial tests an injection called KSVCBD, a type of CAR-T cell therapy, in 60 adults with severe autoimmune diseases like lupus and scleroderma. The goal is to see if it's safe and to get a first look at whether it might help control the disease. Participants recei…

This early-phase study tests a new treatment called BEN301, which uses specially engineered immune cells (CAR-Tregs) to calm overactive immune responses in people with autoimmune diseases like scleroderma, rheumatoid arthritis, lupus, and inflammatory muscle disease. The trial wi…

This early-stage trial will test a new cell therapy called YTS109 in 12 children aged 5 to 17 with severe autoimmune diseases like lupus or scleroderma that have not responded to standard treatments. The children will receive a single infusion of these cells, and researchers will…

This Phase 2 trial tests an experimental drug called ESG206 in 40 adults with primary Sjögren's syndrome, an autoimmune disease causing dry eyes and mouth. The drug targets a protein to reduce immune system attacks on the body. Researchers will compare high and low doses against …

This early-phase trial will test BCT301, a type of immune cell made from stem cells, in 10 people with severe autoimmune diseases like lupus and scleroderma. Participants receive a single infusion of these cells after a short course of chemotherapy. The main goal is to check safe…

This study tests whether two doses of stem cells, given four months apart, can improve saliva production and reduce dry mouth in people who had radiation for head and neck cancer or have Sjögren's disease. One hundred participants will receive either stem cells or a placebo. The …

This early study tests a new treatment called CD19 UCAR-T cells for people with autoimmune diseases like lupus, vasculitis, and Sjögren's syndrome. The therapy uses modified immune cells to target and calm the overactive immune system. The main goals are to check safety and see i…

This early study tests a special contact lens (MSCohi-O) for people with Sjögren's syndrome whose dry eyes don't improve with standard treatments. Twelve participants will wear the lenses for 12 hours a day over 14 sessions. Researchers will check for side effects and measure cha…

This early-stage trial will test an oral probiotic called R-2487 in 36 adults with Sjogren's syndrome. The main goal is to see if the probiotic is safe and tolerable. Researchers will also check for changes in disease activity and inflammation using blood and stool samples. The s…

Researchers are testing an experimental drug called ONO-4915 in adults with primary Sjogren's disease, a condition that causes dryness, fatigue, and pain. The trial enrolls about 60 people who have moderate to severe symptoms and a positive anti-SS-A/Ro antibody. Participants rec…

This early trial tests whether exosome eye drops can safely relieve dry eye symptoms in people with Sjögren's syndrome. Twelve adults whose dry eyes haven't improved with standard treatments will use the drops four times daily for two weeks. The main goal is to check for side eff…

Researchers want to understand the different ways pain works in people with rheumatic diseases such as lupus, rheumatoid arthritis, and Sjogren's syndrome. The study enrolls up to 225 people aged 9 to 85 who have or may have a rheumatic disease, plus healthy volunteers matched by…

Researchers at Assiut University are studying whether rheumatic diseases such as rheumatoid arthritis, lupus, and Sjogren's syndrome harm the meibomian glands, the tiny eyelid glands that keep tears from evaporating. The study compares 120 people with these conditions to 30 healt…

This study investigates whether a protein called FCRL5, found on certain immune cells, can serve as a marker for multiple sclerosis (MS) activity and treatment response. Researchers will track MS patients with blood tests every six months for two years, and compare their results …

This study uses a novel ingestible mini-pill to collect bacteria samples from different parts of the gut in people with Sjögren's disease and healthy volunteers. By comparing these samples with mouth and stool bacteria, researchers hope to understand how the microbiome relates to…

This study follows up with 220 people who previously took part in the Sjögren's International Clinical Collaborative Alliance (SICCA) study at the University of Pennsylvania. Researchers will collect tears, saliva, blood, and other samples, along with eye and mouth exams, to trac…

This study looks at whether measuring a specific antibody, anti-Ro52, in the blood of people with Sjögren's syndrome can help predict who will develop serious problems like lymphoma or organ damage. Researchers will follow 150 patients over time to see if higher antibody levels a…